ArticleBritish journal of pain2026
OnabotulinumtoxinA in refractory postherpetic neuralgia: a case report.
Article in British journal of pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition following herpes zoster, occurring particularly in elderly or immunosuppressed individuals. It is often difficult to treat and may significantly impair quality of life. Case Report: We report the single-blinded treatment of refractory thoracic PHN with onabotulinumtoxinA (BoNT/A). A total of 200 IU was injected into the affected area across 40 injection points (5 IU per site), while one corner of the affected area was injected with saline as an intra-individual blinded comparator. A remaining painful area was treated with a further 100 IU BoNT/A 24 days later. Results: Pain intensity decreased progressively from severe pain with attacks up to 10/10 on the numeric rating scale (NRS) to 5/10 in the BoNT/A-treated area, while the saline-injected area showed no noteworthy improvement. Following the second BoNT/A injection, the remaining painful area reduced further to a coin-sized spot. The clinical effect lasted approximately 3 months and repeated treatment stabilised substantial pain reduction for almost 1 year. Conclusion: BoNT/A may be an effective treatment option in selected patients with refractory focal PHN, particularly when established first- and second-line treatments are ineffective, poorly tolerated or contraindicated. Further controlled studies are required to clarify efficacy, duration of benefit and repeat-treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.